You are viewing the site in preview mode

Skip to main content

Table 4 Clinicopathologic features of iAMP21 positive adolescent B-ALL without ETV6-RUNX1 fusion

From: Coexistence of iAMP21 and ETV6-RUNX1 fusion in an adolescent with B cell acute lymphoblastic leukemia: literature review of six additional cases

Cases Age(Yr)/Gender WBC Count (109/L) Additional Abnormalities RUNX1 Copies/Cell Outcome References
1 15/M 3.1 −8,der(16)t(1;16),−21 5–6 CRb1 × 9 months Johnson, 2015 [11]
2 17/M 2.4 Normal Karyotype >5 Relapsed 58 months after diagnosis following SCT, CR2 × 3 y Johnson, 2015 [11]
3 20/M 2.2 −13,−14,+21 6–7 CR1 × 30 months Johnson, 2015 [11]
4 19/M 5.3 del(7)(q11.2) 5–9 CR alive for 2 years Knez, 2015 [15]
5 13/M 3.7 None 5–10 Unknown Knez, 2015 [15]
6 15/M 2.1 None 4–8 Relapsed after 7 years of CR Knez, 2015 [15]
7 13/F 3.0 +X >5 CR and alive for 3 years Knez, 2015 [15]
8 15/M 15.8 del(7)(q31) 8 Relapse 2.5 y from diagnosis, CR2 at last chemo block Haltrich, 2013 [12]
9 14/M 2.2 None 5–10 CR 29 months Reichard, 2011 [8]
10 15/M 2.0 Not Done 6–8 CR 51 months Reichard, 2011 [8]
11 13/F 2.8 None 5–10 CR 18 months Soulier, 2003 [16]
12 17/M 1.0 add(1)(q25) 8 CR 19 months Soulier, 2003 [16]
13 19/F 10.1 del(7)(p14p21) 6–8 CR 21 months Soulier, 2003 [16]
14 14/M 2.2 inv(7)(p?15q?21) 5–7 CR 23 months Soulier, 2003 [16]
15 13/F 3.8 del(7)(q22q35),del(11)(p12) 5 CR 61 months Soulier, 2003 [16]
16 15/F 9.9 None 4 CR 86 months Soulier, 2003 [16]
17 15/M 4.3 -Y 4–5 CR 32 months Soulier, 2003 [16]
18 15/F NAa add(1)(p?),del(6)(q25) >4 CR 13 months Soulier, 2003 [16]
19 13/M 7.6 i(9)(q10),−16 4 CR 18 months Soulier, 2003 [16]
20 13/F 6.6 add(4)(q31),del(7)(q3?2) 5 CR 10 months Soulier, 2003 [16]
21 14/M 14.5 Normal Karyotype 6–15 CR 48 months Soulier, 2003 [16]
22 15/F NA Normal Karyotype 15–20 Relapsed Soulier, 2003 [16]
  1. a NA not available
  2. b CR complete remission
Back to article page

Molecular Cytogenetics

ISSN: 1755-8166